Gilotrif and Salivary hypersecretion - a phase IV clinical study of FDA data

Summary:

Salivary hypersecretion is reported as a side effect among people who take Gilotrif (afatinib dimaleate), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Diovan, and have Lung cancer - non-small cell.

The phase IV clinical study analyzes which people have Salivary hypersecretion when taking Gilotrif. It is created by eHealthMe based on reports of 6,046 people who have side effects when taking Gilotrif from the FDA, and is updated regularly.

What is Gilotrif?

Gilotrif has active ingredients of afatinib dimaleate. eHealthMe is studying from 6,055 Gilotrif users. Check the latest studies of Gilotrif.

What is Salivary hypersecretion?

Salivary hypersecretion (excess saliva secretion) is found to be associated with 783 drugs and 1,337 conditions by eHealthMe. Check the latest studies of Salivary hypersecretion.

On Aug, 07, 2026

6,046 people reported to have side effects when taking Gilotrif.
Among them, 12 people (0.2%) have Salivary hypersecretion.

Could Gilotrif cause Salivary hypersecretion?

Among these 12 people:

How long have people been on Gilotrif when they have Salivary hypersecretion? *

What is the gender of people who have Salivary hypersecretion when taking Gilotrif? *

female: 91.67 %
male: 8.33 %

What is the age of people who have Salivary hypersecretion when taking Gilotrif? *

What are other drugs people take besides Gilotrif? *

What are other side effects people have besides Salivary hypersecretion? *

Diarrhea: 11 people, 91.67%
Hair Loss: 10 people, 83.33%
Rashes (redness): 9 people, 75.00%
Nausea (feeling of having an urge to vomit): 8 people, 66.67%
Dry Skin: 8 people, 66.67%
Oropharyngeal Pain: 7 people, 58.33%
Muscle Spasms (muscle contraction): 6 people, 50.00%
Swallowing Difficulty: 6 people, 50.00%
Dyspnea (difficult or laboured breathing): 6 people, 50.00%
Fatigue (feeling of tiredness): 5 people, 41.67%

What are the existing conditions these people have? *

Lung Cancer - Non-Small Cell (lung cancer): 11 people, 91.67%
Stress And Anxiety: 6 people, 50.00%
High Blood Pressure: 3 people, 25.00%
High Blood Cholesterol: 3 people, 25.00%
Adverse Event: 3 people, 25.00%
Indigestion: 2 people, 16.67%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 2 people, 16.67%
Cardiac Failure: 2 people, 16.67%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 2 people, 16.67%
Non-Small Cell Lung Cancer Metastatic (type of epithelial lung cancer spreads to other parts): 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Gilotrif and have Salivary hypersecretion?

- Check whether Salivary hypersecretion is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Gilotrif:

Gilotrif (6,055 reports)

Browse all side effects of Gilotrif:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Salivary hypersecretion:

Salivary hypersecretion (783 drugs)

Browse all the conditions that are associated with Salivary hypersecretion:

Salivary hypersecretion (1,337 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on afatinib dimaleate (the active ingredients of Gilotrif) and Gilotrif (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.